Legal challenges to a recent jury verdict in Amgen v Hospira continue, with both parties in the case filing briefs asking for new trials over aspects of the ruling.
Legal challenges to a recent jury verdict in Amgen v Hospira continue, with both parties in the case filing briefs asking for new trials over aspects of the ruling.
Last month, a federal jury found that Hospira had infringed on Amgen’s US Patent Number 5,856,298 (the ‘298 patent), which covers erythropoietin, and ordered the biosimilar developer to pay Amgen, the maker of the reference epoetin alfa (Epogen), $70 million. Hospira had unsuccessfully argued during the trial that its development of a biosimilar product was protected under safe harbor.
In a motion filed this week, Hospira asked the court for a judgment that the manufacture of its batches of a biosimilar product are protected by safe harbor provisions, that Hospira did not infringe on the ‘298 patent (which is states is invalid), and that damages owed to Amgen must not exceed $1.5 million per batch of the drug (if those batches are then sold). In the alternative to such a finding, Hospira asked for a new trial in the case.
Amgen, too, filed a brief in response to the verdict, also asking for a new trial. The jury in Amgen v Hospira found that Hospira had not infringed on US Patent 5,756,349 patent (the ‘349 patent). Amgen claims that “no reasonable jury could have concluded that Hospira did not infringe” on its patent, which is directed toward cells that are capable of producing “large, specified amounts” of erythropoietin (EPO), and that Hospira’s documents that it submitted to the FDA—and presented to the court witness testimony during the trial—establish that its cells fell within the limitations set out in its ‘349 patent. “The jury was not free to disregard the only evidence presented at trial about the EPO production rate of Hospira’s cells,” according to Amgen’s brief.
Finally, Amgen took issue with Hospira’s closing arguments that appropriate data had not proven infringement on the ‘349 patent, saying that the argument had not had supporting testimony during the trial. Amgen seeks a new trial that will specifically address infringement of the ‘349 patent.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.
Review Highlights Most Popular European Policies to Boost Biosimilar Uptake
April 3rd 2024Although tender systems are a common strategy to encourage biosimilar utilization across Europe, policies like automatic substitution are rarely utilized, according to a systematic review of European policies and biosimilar uptake.